NIFTY 50 WEEKLY TOP GAINERS AND LOSERS FROM CAPITALHEIGHT

 NIFTY 50 TOP GAINERS
CapitalHeight

                   NIFTY 50 WEEKLY LOSERS
Today'sTop losers by Capitalheight
               TECHNICAL ANALYSIS STOCK

Technical Analysis by Capitalheight

After making a marginal consolidation, Cadila Healthcare may be give a breakout from doublepattern above Rs 410-415 levels. Volumes during this price action were almost double to its average daily volumes, indicating strong buying interest after this breakout. The Relative strength index (RSI) is making the higher bottom and higher top and MACD is trading with a positive crossover. Traders can buy CADILA healthcare around current level Rs 400-406 with a stop loss below Rs 380 (closing) for target of Rs 425 -440.
Drug firm Cadila has received approval from the US health regulator to market Tadalafil tablets, used to erectile dysfunction, in the American market. The company has received tentative approval from the US Food and Drug Administration (USFDA) to market the drug in strengths of 2.5 mg, 5 mg, 10 mg and 20 mg, Cadila said in a regulatory filing.
For 2 Days Free Trial Click here: Capitalheight.

Resistance and Support by Capitalheight


No comments: